Genmab And AbbVie: Epcoritamab In Combination With R-CHOP Demonstrates Statistically Significant Improvement In Progression-Free Survival In Patients With Newly Diagnosed Diffuse Large B-Cell — Street Insider
READ HERE
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Genmab, AbbVie drug combo shows 51% lower risk of progression in lymphoma trial
The EPCORE DLBCL-2 trial showed that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% compared to R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients.